NCT05164341

.css-1gu7o1h p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1gu7o1h .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}.css-1hgicv7{box-sizing:border-box;-webkit-flex-direction:row;-ms-flex-direction:row;flex-direction:row;}.css-1hgicv7 p{color:#FFFFFF;font-weight:600;font-size:1rem;}.css-1hgicv7 .typo{display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-box-pack:center;-ms-flex-pack:center;-webkit-justify-content:center;justify-content:center;}

JavaScript is currently disabled in your browser. For the best experience, please enable JavaScript to enjoy full website functionality. Thank you!

Steps to Enable JavaScript

Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL

About the study

This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

Diagnosis of Familial Partial Lipodystrophy (FPLD)

EXCLUSION CRITERIA

Exclusion Criteria:

Previous treatment with metreleptin

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details

Contition

Partial Lipodystrophy

Age (in years)

12+

Phase

Phase 3

Participants needed

65

Est. Completion Date

Jan 31, 2026

Treatment type

Interventional

Sponsor

Amryt Pharma

ClinicalTrials.gov identifier

NCT05164341

Study number

APG-20

Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?